On May 15, 2024, Novo Holdings A/S (Novo Holdings) announced the acquisition of a majority stake in Austria-based Single Use Support, a fast-growing life science tools company providing advanced technology solutions for the pharmaceutical production process. Wilson Sonsini Goodrich & Rosati advised Novo Holdings on IP Matters related to the transaction.

Single Use Support, founded in 2017, has emerged as a leader in the industry, providing equipment and supplies for the bioprocessing value chain, with a particular emphasis on biological drug substances, cell and gene therapies, and mRNA vaccines. Novo Holdings is set to take a controlling 60 percent stake with the remaining 40 percent will be divided between the two founders Johannes Kirchmair, Thomas Wurm, and Danaher. The investment will support Single Use Support's global expansion, with a focus on the target markets in the U.S. and Asia. The transaction is subject to regulatory approvals.

Novo Holdings is responsible for managing the assets of Novo Nordisk Foundation, which seeks to improve people’s health and the sustainability of society and the planet. The firm invests in life sciences companies and is an asset manager.

The Wilson Sonsini team that advised Novo Holdings on IP matters related to the transaction includes Maya Skubatch, Darby Chan, Madeline Hess, and Eric Ong.

For more information, please see Novo Holdings' news release. Additional coverage can be found on Reuters, BioSpace, and Fierce Pharma.